Phase 1 N=36 Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function
Hepatic Insufficiency · Healthy
Primary: Area Under the Curve 0 to Infinity (AUC0-∞) — 10800; 13800; 16100; 19000 nmol*h/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=56 Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in the 24-hour Weighted Mean Glucose (WMG) — 11.0; -4.4 mg/dL — p=0.083
Phase 1 N=24 A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)
Psoriasis · Plaque Psoriasis
Primary: Least Squares Mean Percent Change From Baseline (Predose Day 1) of Target Lesion Severity (TLS) Score for Lesions Treated With MK-0873 and Lesions Treated With MK-0873…
Phase 1 N=24 A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Type 2 Diabetes Mellitus
Primary: Effect of Renal Function on Maximum Plasma Concentration of TA-7284 — 1197.1264; 2333.3617; 1213.6571; 2415.6109 ng / mL
Phase 1 N=35 Relative Bioavailability of Olodaterol and Fluconazole
Healthy · Pulmonary Disease, Chronic Obstructive
Primary: Area Under Curve From 0 to 6 Hours at Steady State (AUC0-6,ss) — 19.659; 22.271 Picogram*hours/milliliter — p=0.0101
Phase 1 N=16 Safety Evaluation of Aminophylline and Methazolamide
Mountain Sickness
Primary: Adverse Events. — 29; 40 Events
Phase 1 N=4 Pancreatic Islet Cell Transplantation
Type 1 Diabetes
Primary: Achievement of Insulin Independence at 12-month Post Transplant — 1 participant
Phase 1 N=42 Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults
Pneumococcal Vaccines
Primary: Unsolicited Adverse Event Reports — 7; 6; 5; 6 participants
Phase 1 N=37 A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Non-Small Cell Lung Carcinoma · Breast Cancer · Melanoma
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Phase 1 N=43 Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT
Lymphoma
Primary: Toxicity — 1; 8 participants
Phase 1 N=11 Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium
Asthma · Perennial Allergic Rhinitis
Primary: Number of Reported Treatment-related Adverse Events (AEs) — 0; 0; 0; 0 Events
Phase 1 N=25 Effect of Delivery Route on PK of Sufentanil NanoTab
Pharmacokinetics
Primary: AUC (0 - Inf) — 273.8; 212.5; 163.4; 24.9 h.pg/mL
Phase 1 N=43 Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function
Hepatic Impairment · Healthy
Primary: Area Under the Plasma Concentration-time Curve (AUC) of SSP-004184 — 254327.7; 443053.5; 288579.6; 410414.3 ng*h/ml
Phase 1 N=14 Oxytocin Treatment of Alcohol Withdrawal
Alcohol Withdrawal
Primary: Total Lorazepam Dosage (in Milligrams) — 16.5; 3.4 milligrams of lorazepam
Phase 1 N=6 AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled SSP-004184 — 251438.3 ng*hr/ml